Mirae Asset Global Investments Co. Ltd. Sells 199,301 Shares of Senseonics Holdings, Inc. (NYSE:SENS)

Mirae Asset Global Investments Co. Ltd. lessened its position in Senseonics Holdings, Inc. (NYSE:SENS) by 22.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 698,803 shares of the company’s stock after selling 199,301 shares during the quarter. Mirae Asset Global Investments Co. Ltd. owned about 0.13% of Senseonics worth $398,000 at the end of the most recent quarter.

Separately, Cornerstone Wealth Management LLC increased its holdings in shares of Senseonics by 55.9% during the 3rd quarter. Cornerstone Wealth Management LLC now owns 55,750 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares during the period. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Stock Performance

Shares of Senseonics stock opened at $0.42 on Friday. The company has a debt-to-equity ratio of 1.15, a quick ratio of 7.03 and a current ratio of 7.53. The company’s 50-day simple moving average is $0.55. Senseonics Holdings, Inc. has a twelve month low of $0.38 and a twelve month high of $1.05. The firm has a market cap of $220.66 million, a price-to-earnings ratio of -3.78 and a beta of 0.87.

Senseonics (NYSE:SENS) last issued its earnings results on Thursday, February 29th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. Senseonics had a negative net margin of 270.13% and a negative return on equity of 146.90%. The business had revenue of $8.00 million for the quarter, compared to analyst estimates of $7.62 million. On average, equities analysts forecast that Senseonics Holdings, Inc. will post -0.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Senseonics to a “sell” rating in a report on Friday, March 29th.

Senseonics Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.